Berberine sensitizes liver cancer cells to sorafenib by inducing SETDB1/NQO1/p53-dependent ferroptosis and genomic instability.
As demonstrated from our results, we found berberine greatly enhanced the inhibitory effects of sorafenib on cell proliferation synergistically against mouse and human liver cancer cell lines in vitro, Hepa1-6 xenograft model in C57/B6J mice in vivo and in the 3D culture system of tumor cells.